sulconazole

Trade name: exelderm

Small moleculeapproved

Approved

Aug 30, 1985

Sulconazole (trade name Exelderm) is an antifungal medication of the imidazole class. Sulconazole has a broad spectrum of antifungal activity in vitro and has been shown to be an effective topical antifungal agent for the management of superficial fungal infections of the skin, particularly dermatophytosis and tinea versicolor. Sulconazole inhibits the cytochrome P-450 isoenzyme, C-14-alpha-demethylase by binding to the heme iron of the enzyme. This results in a largely fungistatic effect. The selectivity of azole antifungal agents for pathogenic organisms compared with mammalian cells appears to depend on a preferred affinity of these drugs for fungal versus mammalian cytochrome P-450 sterol demethylases. Enzyme inhibition by sulconazole prevents the synthesis of ergosterol, a sterol found in fungal cell membranes but, in general, not in mammalian cell membranes. Additionally, lanosterol accumulates, which changes membrane permeability, cell volume, secondary metabolic effects, and causes defective cell division and growth inhibition. As sulconazole is primarily fungistatic, an intact immune system may be needed for infection resolution.In selected situations, sulconazole may have growth phase-dependent fungicidal activity against very susceptible organisms. The 1% concentration of sulconazole may greatly exceed the minimum inhibitory concentration and exert a direct physiochemical effect on the fungal cell membrane. The fungicidal effect may be due to hydrophobic interactions between sulconazole and unsaturated fatty acids in the membrane. Mammalian cells generally have little or no unsaturated fatty acids. Sulconazole may also prevent DNA and RNA synthesis and increase their degradation.Sulconazole has activity against many dermatophytes and yeast. One measure of the drug's antifungal activity is the relative inhibition factor (RIF). The RIF approaches 0% for a drug to which a fungus is highly sensitive and 100% for a drug that is non-inhibitory. The RIF values of sulconazole for Candida species, Aspergillus species, and dermatophytes are broadly similar to those of clotrimazole, econazole, ketoconazole, miconazole, and tioconazole. The mean RIF values were 69% (30—98%) for Candida species, 71% (61—82%) for Aspergillus species, and 12% (5—18%) for dermatophytes. Sulconazole is available as a cream or solution to treat skin infections such as athlete's foot, ringworm, jock itch, and sun fungus. — NCATS

Clinical trial activity

0 trials · 0 clinical orgs · 1 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Timeline

1980s

  1. Aug 30, 1985

    Earliest FDA Approval

  2. Aug 30, 1985

    Fortress Biotech — NDA Secondary Org

  3. Feb 18, 1989

    Fortress Biotech — First NDA Organization

  4. Feb 18, 1989

    Fortress Biotech — NDA Organization

Indications

Mechanism of action

Approval history

  • approvedAug 30, 1985

Chemistry & pharmacology

Loading structure…

SMILES

Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1
Mol. weight
397.76 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Topical
Availability
Prescription Only

Oral

No

Parenteral

No

Topical

Yes

Sources

Also known as

  • 1-(beta-(4''-chlorobenzylthio)-2'4'-dichlorophenethyl)imidazole
  • exelderm
  • exelderm
  • exelderm
  • exelderm
  • myk
  • rs-44872
  • rs-44872
  • rs-44872-00-10-3
  • rs-44872-00-10-3
  • rs-44872-00-1o-3
  • rs-44872-00-1o-3
  • sulconazole
  • sulconazole
  • sulconazole
  • sulconazole
  • sulconazole
  • sulconazole
  • sulconazole
  • sulconazole
  • sulconazole
  • sulconazole mononitrate
  • sulconazole, mononitrate, (+-)-isomer
  • sulconazole nitrate
  • sulconazole nitrate
  • sulconazole nitrate
  • sulconazole nitrate
  • sulconazole nitrate

Organizations

Marketing (2)

OrganizationOrg typeRelationshipDate
Fortress BiotechFor profitNDA2Aug 30, 1985
Fortress BiotechFor profitNDAFeb 18, 1989